Inclusion Criteria:  Patients with confirmed diagnosis of r/r iNHL Patients ages ≥ 18 years old when first dosed with copanlisib for iNHL. Patients who will receive copanlisib or received at least one dose of copanlisib after 01-Nov-2019 Patients or his/her legal guardian or representative agree to provide the written informed consent or a waiver of informed consent granted by local IRB  Exclusion Criteria:  Patients who had participated in the global clinical study for copanlisib before local market approval Patients who participate in an interventional trial during the data collection period